[DOI] [PubMed] [Google Scholar] 148.Lynch K.E., Feldman H.I., Berlin J.A., Flory J., Rowan C.G., Brunelli S.M
A critical evidentiary hearing is set for May 14, 2025, where U.S
Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR (2011) Rethinking ovarian cancer: recommendations for improving outcomes
This multimodal approach connected known T2D GWAS variants through an RFX6 -regulated gene network and identified novel non-coding RFX6 variants causally associated with diabetes development, placing RFX6 at the center of a complex genetic network that increases the risk of T2D
The combined GLP-1/GIP signal in tirzepatide is the mechanistic basis for its ~22.5% SURMOUNT-1 result, outperforming semaglutide's STEP 1 figure by roughly 7.6 percentage points
The modified nanoparticles exhibited good cytotoxicity against MCF7 cell lines
